J&J Starts The Year With A Bang: 22 Early-Stage Deals
This article was originally published in Scrip
Johnson & Johnson revealed 22 research collaborations and partnerships on Jan. 7, running the gambit across the company's diversified business and highlighting its emphasis on tapping external sources for innovation.
You may also be interested in...
Scrip's second full day of meetings and events during the annual BIO International Convention delivered diverse insights about including patients in drug development, sharing risk with CROs, microbiome-targeting therapies, and the benefits of incubating early-stage technology.
Interview: CEO Jean-Paul Kress talked to Scrip about the US launch of Monjuvi, commercial expansion and the aspiration to build a European biotech that can compete in the big leagues.
Categories from asthma to high blood pressure to cancer showed reductions in new medication users in 2020, likely caused by fewer new diagnoses because of the pandemic, a report from Cigna’s Evernorth shows.